Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coltuximab ravtansine
- Development stage
- Phase 2
- Lead developer
- ImmunoGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Coltuximab ravtansine is an investigational antibody-drug conjugate composed of a chimeric monoclonal antibody targeting B-lymphocyte antigen CD19, a B-cell surface antigen, conjugated to the cytotoxic maytansinoid DM4 via a disulfide linker. The drug selectively binds to CD19 on B cells, leading to internalization and intracellular release of DM4, which inhibits tubulin polymerization and microtubule assembly. This mechanism disrupts cell division and induces apoptosis in malignant B cells. Coltuximab ravtansine was developed primarily for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and has also been investigated in precursor cell lymphoblastic leukemia/lymphoma. The drug was originally developed by ImmunoGen (now part of AbbVie), with clinical trials reaching phase II for DLBCL[1][2][3][4][5].
- Other names
- Maytansin-loaded anti-CD19 mAb
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on coltuximab ravtansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coltuximab ravtansine.